18 November 2017 - Single-use drugs that could cure diseases are valuable -- but wildly expensive.

Drugs that modify human genes have the potential to cure intractable diseases with just one treatment. Few could disagree that's a good thing. But if these same drugs cost $1 million or more a pop, then the disagreements begin.

Philadelphia gene-therapy maker Spark Therapeutics Inc. -- whose eye-disease drug is likely to be the first such medicine approved for use in the U.S. -- generated backlash recently for suggesting such a high price may be justified. As more of these medicines hit the market, conflict will likely grow between those who make them and those who must pay for them.

Read Bloomberg article